To determine whether the degree of changes in cardiac parameters and systemic oxidative stress 2 weeks after completion of doxorubicin treatment was different between HER2-positive and HER2-negative breast cancer patients, the absolute changes in these parameters were compared between these two groups of patients. The gene discussed is ERBB2; the disease is breast carcinoma.